Search results
Testing for residual cancer cells before blood cell transplant therapy is important and practical,...
Medical Xpress· 20 hours ago"The good news is this testing is doable," said Christopher Hourigan, a Virginia Tech professor of...
...for Treatment of Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic...
WFRV 5 Green Bay· 24 hours agoAdditionally, the company also announced that REM-422 has received Orphan Drug Designation from the FDA for the treatment of ACC and AML...
I-95 in Connecticut will close for days after fiery crash damages bridge, governor says
The Republican· 12 hours agoThe major traffic artery linking New England with New York will be closed in Connecticut for days...
Cullinan Oncology (NASDAQ:CGEM) Now Covered by Stifel Nicolaus
ETF DAILY NEWS· 5 hours agoAnalysts at Stifel Nicolaus initiated coverage on shares of Cullinan Oncology (NASDAQ:CGEM – Get Free Report) in a report released on Wednesday, Marketbeat Ratings reports. The brokerage set ...
Grandmother, granddaughter fight cancer together
The Port Lavaca Wave· 20 hours agoWhen faced with cancer at the same time, a grandmother and her grandchild are strengthening their bond as they fight together. Calhoun High School...
More bones found in Mass. creek where skull was discovered
The Republican· 16 hours agoAdditional human bones were found in Easton on Thursday as officials continued to search the area...
Moleculin Announces Formation of Scientific Advisory Board to Support Development of Annamycin
KTLA-TV Los Angeles· 2 days agoMartin Tallman. Dr. Tallman is an internationally renowned clinical investigator whose discoveries have fueled the progress of leukemia-targeting therapies, most recently ...
BMO Capital Markets Lowers Incyte (NASDAQ:INCY) Price Target to $52.00
ETF DAILY NEWS· 5 hours agoIncyte (NASDAQ:INCY – Get Free Report) had its price target cut by BMO Capital Markets from $56.00 to $52.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently ...
MorphoSys Says Novartis Deal Progressing Steadily Despite Safety Concerns Over Bone Marrow Cancer...
Benzinga· 4 days agoMorphoSys AG MOR is reportedly facing a burgeoning safety concern surrounding pelabresib, an...
Affimed (NASDAQ:AFMD) Short Interest Update
ETF DAILY NEWS· 4 days agoAffimed (NASDAQ:AFMD – Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 219,400 shares, an increase ...